 |
|
Effects of Antibiotic Therapy on Outcomes of Patients With Coronary Artery Disease
A Meta-analysis of Randomized Controlled Trials
Richard Andraws, MD;
Jeffrey S. Berger, MD;
David L. Brown, MD
JAMA. 2005;293:2641-2647.
Context Although Chlamydia pneumoniae infection has been associated with the initiation and progression of atherosclerosis, results of clinical trials investigating antichlamydial antibiotics as adjuncts to standard therapy in patients with coronary artery disease (CAD) have been inconsistent.
Objective To conduct a meta-analysis of clinical trials of antichlamydial antibiotic therapy in patients with CAD.
Data Sources The MEDLINE and Cochrane Central Register of Controlled Trials databases were searched from 1966 to April 2005 for English-language trials of antibiotic therapy in patients with CAD. Bibliographies of retrieved articles were searched for further studies. Presentations at major scientific meetings (2003-2004) were also reviewed. Search terms included antibacterial agents, myocardial infarction, unstable angina, and coronary arteriosclerosis.
Study Selection Eligible studies were prospective, randomized, placebo-controlled trials of antichlamydial antibiotic therapy in patients with CAD that reported all-cause mortality, myocardial infarction, or unstable angina. Of the 110 potentially relevant articles identified, 11 reports enrolling 19 217 patients were included.
Data Extraction Included studies were reviewed to determine the number of patients randomized, mean duration of follow-up, and end points. End points of interest included all-cause mortality, myocardial infarction (MI), and a combined end point of MI and unstable angina.
Data Synthesis Event rates were combined using a random-effects model. Antibiotic therapy had no impact on all-cause mortality among treated vs untreated patients (4.7% vs 4.6%; odds ratio [OR], 1.02; 95% confidence interval [CI], 0.89-1.16; P = .83), on the rates of MI (5.0% vs 5.4%; OR, 0.92; 95% CI, 0.81-1.04; P = .19), or on the combined end point of MI and unstable angina (9.2% vs 9.6%; OR, 0.91; 95% CI, 0.76-1.07; P = .25).
Conclusion Evidence available to date does not demonstrate an overall benefit of antibiotic therapy in reducing mortality or cardiovascular events in patients with CAD.
Author Affiliations: Cardiovascular Medicine, Department of Medicine, Beth Israel Medical Center, New York, NY (Drs Andraws and Berger) and Division of Cardiovascular Medicine, State University of New York-Stony Brook School of Medicine, Stony Brook (Dr Brown).
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
The role of infection in cardiovascular disease: more support but many questions remain
Smeeth et al.
Eur Heart J 2007;28:1178-1179.
FULL TEXT
Azithromycin for the secondary prevention of coronary artery disease: A meta-analysis
Baker and Couch
Am J Health Syst Pharm 2007;64:830-836.
ABSTRACT
| FULL TEXT
Oxidized Low-Density Lipoprotein Autoantibodies, Chronic Infections, and Carotid Atherosclerosis in a Population-Based Study
Mayr et al.
J Am Coll Cardiol 2006;47:2436-2443.
ABSTRACT
| FULL TEXT
Randomised placebo controlled multicentre trial to assess short term clarithromycin for patients with stable coronary heart disease: CLARICOR trial
Jespersen et al.
BMJ 2006;332:22-27.
ABSTRACT
| FULL TEXT
Evidently ...
LEHMAN
Evid. Based Med. 2005;10:167-167.
FULL TEXT
Other articles noted
Evid. Based Med. 2005;10:191-192.
FULL TEXT
What's Bugging You?
Leslie
Sci Aging Knowl Environ 2005;2005:ns2-ns2.
ABSTRACT
| FULL TEXT
Standard CAD Care Should Not Include Antibiotics
Journal Watch Cardiology 2005;2005:6-6.
FULL TEXT
What's new in the other general journals
Martyn
BMJ 2005;330:1351-1351.
FULL TEXT
|
